This article is more than 5 years old. Information may no longer be current.

Iridex increases ophthalmic product sales in third quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MOUNTAIN VIEW, Calif. — Third quarter sales for ophthalmic device maker Iridex were $6.7 million, about the same level as the corresponding quarter in 2001, the company announced.

Sales of the company’s ophthalmology products rose 13.5% in the third quarter to $5.4 million. This offset a decrease in sales for the company’s aesthetic products.

“We are very pleased with the performance within our ophthalmology business,” said Thomas Boutacoff, president and chief executive officer of Iridex. “Our efforts over the past year to direct our focus on our core ophthalmology business has been the key to stabilizing our company during this period of economic uncertainty.”